Companies › SPARK Biopharma
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Respiratory; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SB17170 | – | Phase 2 | IPF; Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06747923 | SB17170 | Phase 2 | IPF | Respiratory | May 2026 |
| NCT05522868 | SB17170 | Phase 1 | Solid Tumor | Oncology | Jun 2027 |
No annotated target.
–
NuvOx MiNK Therapeutics Nanjing RegeneCore Biotech Guangzhou JOYO Pharma Shanghai Guangsheng Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.